{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Brifentanii, a potent narcotic analgesic structurally similar to alfentanil, that was studied in clinical trials in the early 1990s. The effects of brifentanil are very similar to those of alfentanil, with strong but short lasting analgesia and sedation, and particularly notable itching and respiratory depression. Side effects of Brifentanii are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening.
Status:
Investigational
Source:
NCT01039597: Phase 1/Phase 2 Interventional Unknown status Mild to Moderate Ulcerative Colitis
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ore Pharmaceuticals developed ORE1001 previously known as MLN-4760 as an orally administered, small molecule compound, for the treatment of inflammatory bowel diseases. ORE1001 is a specific angiotensin-converting enzyme 2 inhibitor. It was shown that ORE1001 markedly decreased tissue myeloperoxidase activity, a well-known marker of inflammation. As a result, ORE1001 was studied as a treatment of gastrointestinal inflammatory conditions. ORE1001 was involved in phase I clinical trial to investigate its safety and activity in subjects with ulcerative colitis. In addition, the drug was studied for NSAID-induced ulcer and obesity. However, all these studies were discontinued.
Status:
Investigational
Source:
INN:fosalvudine tidoxil [INN]
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Heidelberg Pharma Research developed fosalvudine tidoxil, a prodrug derived from the nucleoside reverse transcriptase inhibitor alovudine, for the treatment of HIV infections. This drug had reached phase II clinical trials before its development was discontinued.
Status:
Investigational
Source:
INN:locnartecan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02928211: Phase 1 Interventional Unknown status Mild Cognitive Impairment
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Aftobetin, also known as ANCA11 and NCE-11, is a novel amyloid–binding compound applied topically in the form of an ophthalmic ointment. Aftobetin offers a promising way for a noninvasive eye-scan to diagnose Alzheimer’s disease early.
Status:
Investigational
Source:
NCT02204644: Phase 3 Interventional Completed CML, CML-CP,MMR,TKI
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Flumatinib (HHGV678) is an orally bioavailable antineoplastic tyrosine kinase inhibitor. Flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. Flumatinib was extensively metabolized after oral administration, and the major metabolic pathways observed were amide hydrolysis, demethylation, oxidation, and glucuronide conjugation. It is in phase III clinical trials for the treatment of Chronic myeloid leukemia (in China).
Status:
Investigational
Source:
NCT01004315: Phase 3 Interventional Completed Overactive Bladder
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.
Status:
Investigational
Source:
NCT01730768: Phase 2 Interventional Completed Schizophrenia
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00268879: Phase 3 Interventional Completed Irritable Bowel Syndrome
(2005)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Renzapride (BRL-24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist. This compound has a stimulatory effect on gastrointestinal motility and transit. Renzapride has been evaluated for use in treatment of irritable bowel syndrome (IBS). Data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. Phase III clinical trials investigated if this drug could help alleviate the symptoms associated with this type of IBS. However, one phase III study has been terminated due to inefficient efficacy (compared to placebo).
Status:
Investigational
Source:
NCT04696848: Phase 1/Phase 2 Interventional Terminated Colorectal Cancer
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
CKD-516 is a prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting, and antineoplastic activity. Upon administration, tubulin polymerization inhibitor CKD-516 is converted into its active metabolite S-516, which binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. CKD-516 is developed by a Korean company Chong Kun Dang Pharmaceutical Corp. and is investigated in a phase 1/2a clinical trial for the treatment of colorectal cancer in combination with Irinotecan.
